Evidence map›Paper›PMID 37045984›Full record

ArticleLeukemia2023

Osteocyte-derived exosomes confer multiple myeloma resistance to chemotherapy through acquisition of cancer stem cell-like features.

Feifei Cheng, Zhiming Wang, Gichun You, Yuhong Liu, Jin He, Jing Yang

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 10 citations in OpenAlex.

  1. Niches in cancer: from primary tumors to metastatic disease.Journal of hematology & oncology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Feifei Cheng *Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3234-513X
Zhiming Wang *Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.
Gichun YouHouston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.
Yuhong LiuDepartment of Chemistry, The University of Tokyo, Tokyo, Japan.
Jin HeHouston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.
Jing YangHouston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA. jyang2@houstonmethodist.org.ORCID http://orcid.org/0000-0001-5143-160X
Houston Methodist · USThe University of Tokyo · JP

Funding

Role of integrin VLA-6 in suppression of bone formation in myelomaR01CA193362 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2016 to 2020
$1.8M
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myelomaR01CA190863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2015 to 2019
$1.8M
NCI NIH HHS CA190863NCI NIH HHS CA193362
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ExosomesMultiple MyelomaHumansNeoplastic Stem CellsOsteocytesSignal Transduction

Identifiers

PMID37045984
OpenAlexW4365146631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.